Slide 1: Sustainability update
Sustainability update For investors and analysts 6 July 2026
Slide 2: Cautionary statements regarding forward-looking statements
Cautionary statements regarding forward-looking statements In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act of 1995, AstraZeneca (hereafter 'the Group') provides the following cautionary statement: This document contains certai
Slide 3: Pam Cheng
Pam Cheng Executive Vice President, Global Operations, IT & Chief Sustainability Officer
Slide 4: Our changing world requires concerted action for a healthier future
Our changing world requires concerted action for a healthier future The climate crisis is worsening the burden of disease Health systems are unable to cope with rising demands Health disparities are widening within and between countries 4
Slide 5: Transformative technologies to drive 2030+ growth
Transformative technologies to drive 2030+ growth Weight Antibody drug Next-generation Cell therapy and Gene therapy management conjugates and immuno-oncology and gene editing T-cell engagers and risk factors radioconjugates bispecifics Establish and lead Replace systemic Replace existing Develop sc
Slide 6: Our Sustainability strategy
Our Sustainability strategy Sustainability impact: Through the power of science and innovation, we are taking action on climate and nature, health equity and health systems resilience. How we do business: We are guided by our Values and invest in our people to create long- term value, resilience and
Slide 7: Delivering for patients sustainably: Climate and Nature
Delivering for patients sustainably: Climate and Nature 88% >80% 1st 81% 23% Reduction in Supplier spend Inhaled Global vehicle Reduction in Scope 1 & 2 with respiratory fleet are water greenhouse gas companies medicine battery electric withdrawal emissions vs committed to approved using vehicles an
Slide 8: Delivering for patients sustainably: Health Equity
Delivering for patients sustainably: Health Equity >40% >60 49m+ 156m of our genomics partnerships with people reached with people in data comes from NGOs through our health education, underserved under-represented Young Health screening and early communities populations Programme detection since 20
Slide 9: Delivering for patients sustainably: Health Systems Resilience
Delivering for patients sustainably: Health Systems Resilience 37 >30 >200 countries with Partnership reports launched with policymakers engaged on for Health System policy recommendations health systems Sustainability & Resilience on how to act early on strengthening and (PHSSR) projects NCDs and s
Slide 10: Our Sustainability targets to 2030
Our Sustainability targets to 2030 Climate and nature Health equity Health systems resilience • 35% reduction in Scope 3 • 1 billion people positively • 45 countries with health systems emissions* impacted, including 400 million strengthened through partnerships • >100m trees planted through AZ from
Slide 11: 2030 target: 35% reduction in Scope 3 emissions
2030 target 35% reduction in Scope 3 emissions vs 2015 baseline Collaborating with Next Generation Reducing environmental suppliers Propellant for inhalers footprint of our products Sustainable Transition from air to Responsible business buildings sea freight travel
Slide 12: Transitioning to next-generation propellant (NGP) for inhaled medicines
Transitioning to Transition timeline next-generation propellant (NGP) for inhaled medicines, First Positive EU Transition Broad with near-zero global industry-wide CHMP progress portfolio warming potential approval opinion (Breztri/Trixeo *) transition Pressurised Endorsed for use Transition complet
Slide 13: 2030 target: 1 billion people positively impacted
2030 target 1 billion people positively impacted including 400 million from underserved groups Determinants of health outcomes Behavioural Early Precision Guideline- Treatment Social Genetic detection diagnostics based care adherence Sustainable Responsible and disease Environmental buildings busine
Slide 14: Our Health Equity strategy
Our Health Equity strategy We aim to deliver health equity impact across key focus areas to close healthcare gaps among underserved patients, so that more people can benefit from innovative medicines. Science Healthcare delivery Community investment • Ensuring more individuals • Improving equitabl
Slide 15: Sustainability is a core part of our business strategy
Sustainability is a core part of our business strategy 15
Slide 16: Q&A
Q&A Pam Cheng Stefan Weber EXECUTIVE VICE PRESIDENT, VICE PRESIDENT, POLICY, ADVOCACY GLOBAL OPERATIONS, AND HEALTH EQUITY IT & CHIEF SUSTAINABILITY OFFICER Liz Chatwin VICE PRESIDENT, Philip Sparks GLOBAL SUSTAINABILITY AND SAFETY, DIRECTOR, INVESTOR RELATIONS HEALTH & ENVIRONMENT 16